Tag: Antibody Therapeutics

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Currently, six of these therapies are commercially available, while around 140 molecules are under development majorly for oncological disorders. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. This has opened a new target space for the development of antibody therapeutics

Since the approval of Enbrel®, CD4 – Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion protein therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion protein based drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates to be recognized as potent therapies (ADC therapy) targeting a wide range of indications, including solid tumors and hematological malignancies. ADC therapy is an engineered therapy comprised of